Deborah Outwater, MD
Family Medicine · Wichita, KSNPI 1073566618
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.7% of it on its own, with 57 other manufacturers making up the rest. Reporting peaked in 2020 at $10,380 and has fallen 81.2% since, to $1,949 in 2025. Among family medicine clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 828 payments — averaging $29.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Pfizer$933
- GSK$579
- plus $4K from 52 others
What the payments were for
- Speaking & faculty fees$13,37554%
- Travel & lodging$6423%
- Food & beverage$10,60343%
- Education$1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,799 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $88,590 |
| XifaxanRifaximin | 14 | $53,062 |
| FarxigaDapagliflozin Propanediol | 43 | $45,986 |
| MounjaroTirzepatide | 43 | $45,463 |
| EliquisApixaban | 32 | $39,890 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $36,827 |
| TrulicityDulaglutide | 33 | $36,627 |
| XareltoRivaroxaban | 22 | $28,685 |
| JardianceEmpagliflozin | 25 | $26,280 |
| MyrbetriqMirabegron | 34 | $26,123 |
| GemtesaVibegron | 23 | $15,187 |
| LinzessLinaclotide | 18 | $14,654 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $13,700 |
| JanuviaSitagliptin Phosphate | 13 | $12,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,684 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,720 | $88,59071 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,043 | $82,09076 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $420 | $53,06214 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $118 | $48,26554 claims |
| AstraZenecaFarxiga | $1,032 | $45,98643 claims |
| PfizerEliquis, Paxlovid | $933 | $41,31947 claims |
| Johnson & JohnsonXarelto | $137 | $28,68522 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $26,12334 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $579 | $20,91135 claims |
| AbbVieLinzess, Synthroid | $15,289 | $18,27452 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $162 | $15,18723 claims |
| MerckJanuvia | $189 | $12,03813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Wichita
- Mila MeansWichita$241K
- Cole GillenwaterWichita$62K
- Hai TruongWichita$25K
- Joseph SackWichita$21K
- Scott StringfieldWichita$20K
- Mark LeikerWichita$20K
- Paul DavisWichita$18K
- Tara NeilWichita$16K
- William SimonWichita$14K
- Angela LeikerWichita$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.